Portage Biotech Stock (NASDAQ:PRTG)
Previous Close
$5.51
52W Range
$2.10 - $58.60
50D Avg
$4.56
200D Avg
$9.15
Market Cap
$5.74M
Avg Vol (3M)
$1.78M
Beta
96.71
Div Yield
-
PRTG Company Profile
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
PRTG Performance
Peer Comparison
Ticker | Company |
---|---|
FREQ | Korro Bio, Inc. |
CUE | Cue Biopharma, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
ARVN | Arvinas, Inc. |
VECT | VectivBio Holding AG |
DBTX | Decibel Therapeutics, Inc. |
BPMC | Blueprint Medicines Corporation |
DAWN | Day One Biopharmaceuticals, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
JANX | Janux Therapeutics, Inc. |
INZY | Inozyme Pharma, Inc. |
KROS | Keros Therapeutics, Inc. |
HRMY | Harmony Biosciences Holdings, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
KRTX | Karuna Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |